Imperial and CNRS open AI lab to tackle metabolic disease

TL;DR:

• Imperial College London and France’s National Centre for Scientific Research (CNRS) have launched a joint lab applying AI to metabolic health.
• The Antoine Lavoisier laboratory will combine machine learning, clinical data and experimental biology to study cancer, diabetes, cardiometabolic and neurodegenerative disease.
• It is Imperial’s third International Research Laboratory with CNRS and was launched alongside the UK-France Joint Committee on Science, Technology and Innovation.

The lab will map how metabolic processes differ between individuals and shift over time, using AI to support earlier risk prediction, more personalised treatment and data-driven tools for healthcare decisions. The scale of the underlying problem is stark: an estimated one billion people are expected to be living with obesity by 2030, and diabetes is projected to affect 1.3 billion by 2050.

A bet on AI-driven biology

Named after the chemist who helped found the study of metabolism, the laboratory reflects a wider shift in which machine learning is treated as core scientific infrastructure rather than a bolt-on. By fusing clinical datasets with experimental biology, researchers aim to spot patterns across conditions — from cardiovascular disease to dementia — that single-disease studies miss.

Imperial President Hugh Brady said the work would “put the UK and France at the forefront” of the field. The collaboration deepens an already substantial relationship: Imperial publishes around 1,400 papers a year with French partners and runs joint maths and engineering labs with CNRS, the latter opened by President Macron last year.

For the UK, the launch is a quiet but meaningful signal of research capacity at a time when scientific competitiveness and international partnerships carry strategic weight. Cross-border labs pool talent, data and funding that neither side could marshal alone — and AI-enabled health research is precisely the kind of high-value science the UK is keen to anchor domestically rather than cede.

Looking forward

The harder work lies ahead: translating pattern-finding into diagnostics and therapies that reach patients. If the Antoine Lavoisier lab delivers usable decision tools, it could strengthen the case for sustained UK-France science cooperation and for AI’s role in tackling the chronic diseases that increasingly strain health systems on both sides of the Channel.